0.22

0.00% 0.00

Pds Biotechnology Corp (PDSB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Pds Biotechnology Corp stock is traded at $0.22, with a volume of 1.08M. It is up +0.00% in the last 24 hours and down -69.44% over the past month. PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Previous Close:

$0.22

Open:

$0.22

24h Volume:

1.08M

Relative Volume:

0.85

Market Cap:

$12.31M

Revenue:

Net Income/Loss:

$-33.36M

P/E Ratio:

-0.3281

EPS:

-0.6706

Net Cash Flow:

$-23.09M

1W Performance:

+4.31%

1M Performance:

-69.44%

6M Performance:

-68.57%

1Y Performance:

-81.97%

1-Day Range:

$0.2174

$0.2378

1-Week Range:

$0.1972

$0.2378

52-Week Range:

$0.1952

$1.55

Pds Biotechnology Corp Stock (PDSB) Company Profile

Name

Pds Biotechnology Corp

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

800-208-3343

Address

303A COLLEGE ROAD EAST, PRINCETON

Employee

Twitter

@pdsbiotech

Next Earnings Date

2026-08-12

Latest SEC Filings

PDSB's Discussions on Twitter

Compare PDSB vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PDSB Pds Biotechnology Corp	0.22	11.69M	0	-33.36M	-23.09M	-0.6706
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-22	Initiated	B. Riley Securities	Buy
Jun-28-21	Initiated	Cantor Fitzgerald	Overweight
Nov-10-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-27-20	Initiated	Alliance Global Partners	Buy
Mar-09-20	Initiated	Noble Capital Markets	Outperform
Oct-24-19	Initiated	Chardan Capital Markets	Buy

View All

Pds Biotechnology Corp Stock (PDSB) Latest News

Aug 20, 2026

PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine

Aug 20, 2026

Aug 19, 2026

Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026

PDS Biotechnology announces CFO resignation and interim appointments - Investing.com

Aug 19, 2026

PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView

Aug 19, 2026

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan

Aug 19, 2026

Aug 18, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 18, 2026

Aug 17, 2026

Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView

Aug 17, 2026

Aug 14, 2026

PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com

Aug 14, 2026

Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan

Aug 14, 2026

Aug 13, 2026

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan

Aug 13, 2026

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 13, 2026

PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade

Aug 13, 2026

Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa

Aug 13, 2026

PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView

Aug 13, 2026

PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative

Aug 13, 2026

PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times

Aug 13, 2026

PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com

Aug 13, 2026

PDS Biotech Q2 FY26 net loss widens to $9.8 million; R&D expense falls 22.49% to $3.3 million - Bitget

Aug 13, 2026

Aug 11, 2026

PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0

Aug 11, 2026

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com

Aug 11, 2026

PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa

Aug 11, 2026

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga

Aug 11, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Aug 11, 2026

Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria

Aug 11, 2026

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net

Aug 11, 2026

PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView

Aug 11, 2026

PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com

Aug 11, 2026

PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative

Aug 11, 2026

PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan

Aug 11, 2026

Aug 09, 2026